论文部分内容阅读
目的探讨分析西妥昔单抗联合放化疗治疗进展期鼻咽癌的临床疗效。方法回顾性分析2010年5月~2013年2月间在本院进行治疗的126例进展期鼻咽癌患者的临床记录资料。结果治疗后,治疗组总有效率为90.48%,显著高于对照组的76.19%,差异具有统计学意义(P<0.05);治疗组的皮疹发生率和口腔黏膜炎发生率均高于对照组,差异具有统计学意义(P<0.05)。结论西妥昔单抗联合放化疗治疗进展期鼻咽癌的临床疗效显著,但不良反应较多,应于临床综合考虑后应用。
Objective To investigate the clinical efficacy of cetuximab in combination with chemoradiotherapy in the treatment of advanced nasopharyngeal carcinoma. Methods The clinical records of 126 patients with advanced nasopharyngeal carcinoma treated in our hospital from May 2010 to February 2013 were retrospectively analyzed. Results After treatment, the total effective rate of the treatment group was 90.48%, which was significantly higher than that of the control group (76.19%), the difference was statistically significant (P <0.05); the incidence of rash and the incidence of oral mucositis in the treatment group were higher than those in the control group , The difference was statistically significant (P <0.05). Conclusion The clinical efficacy of cetuximab in combination with chemoradiotherapy for advanced nasopharyngeal carcinoma is significant, but there are more adverse reactions. It should be used after comprehensive clinical consideration.